Johnson and Johnson (J&J) has achieved Q2 revenues totalling around $25.3bn, representing a year-over-year (YoY) uptick of 6.6%, with the company’s medtech division, J&J MedTech, accounting for more than a third of the total.
J&J MedTech achieved revenues of around $8.93bn in Q2, indicative of a YoY uptick of 4.5%
Meanwhile, the remaining Q2 revenue, comprising pharma products grouped under J&J’s Innovative Medicine business, drew in total Q2 revenues of around $16.4bn. With the release of the life sciences giant’s Q2 results, it now expects earnings to fall in the $11.60-$11.75 per share range for 2026, up from its previously mooted range of $11.45-$11.65. Despite its Q2 results prompting an uplift to its 2026 expectations, J&J’s shares on the Nasdaq were down by around 1.5% at $250.09 at market open on 15 July, versus a prior close of $253.85.
J&J has a market cap of around $611bn. The stock hit is likely due to the fact that J&J MedTech’s revenues of $8.93bn came in below analysts’ average estimate of $8.97bn, according to data compiled by the London Stock Exchange Group (LSEG) and seen by Reuters. For J&J MedTech, the company said that growth throughout the quarter was primarily driven by segments including its electrophysiology products and Shockwave intravascular lithotripsy (IVL) system in cardiovascular diseases.